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Advances in immunotherapy have improved survival of
patients with systemic lupus erythematosus who now face an
increasing burden of chronic diseases including that of the
kidney. As systemic inflammation is also thought to
contribute directly to the progression of chronic kidney
disease (CKD), we assessed this risk in patients with lupus,
with and without a diagnosis of nephritis, and also identified
modifiable risk factors. Accordingly, we enrolled 631 patients
(predominantly Caucasian), of whom 504 were diagnosed
with lupus within the first year and followed for an average
of 11 years. Despite the presence of a chronic inflammatory
disease, the rate of decline in renal function of 238 patients
without nephritis was similar to that described for non-lupus
patient cohorts. Progressive loss of kidney function
developed exclusively in patients with lupus nephritis who
had persistent proteinuria and dyslipidemia, although only
six required dialysis or transplantation. The mortality rate was
16% with half of the deaths attributable to sepsis or cancer.
Thus, despite the presence of a systemic inflammatory
disease, the risk of progressive CKD in this lupus cohort was
relatively low in the absence of nephritis. Hence, as in
idiopathic glomerular disease, persistent proteinuria and
dyslipidemia (modifiable risks) are the major factors for CKD
progression in lupus patients with renal involvement.
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The focus of care of patients with systemic lupus erythema-
tosus (SLE) has traditionally emphasized control of life-
threatening disease flares, and less attention has been paid to
the potential burden of chronic kidney disease (CKD).
Recognized as a global public health problem, CKD is
associated with a high risk of mortality, end-stage renal
disease, and cardiovascular disease; prevention of progressive
CKD is therefore a priority.1 Emerging research suggests that
systemic inflammation contributes directly and indirectly
to progressive CKD.2–4 This paradigm would suggest that
patients with a systemic inflammatory disease such as SLE
face a risk of progressive CKD, even in the absence of specific
autoimmune kidney involvement (that is, nephritis). Im-
paired renal function is not only a risk factor for end-stage
renal disease but CKD may also contribute to the high
cardiovascular risk observed in patients with SLE.5–11
The long-term course of renal function in patients with
SLE without autoimmune kidney involvement (according to
the American College of Rheumatology (ACR) criteria12) is
not well described; however, given the prevailing hypothesis
linking inflammation and CKD, it is plausible that this is
a vulnerable population. In addition to the presence of
systemic inflammation, medication toxicity (drug-related
hypertension and metabolic abnormalities, use of nephro-
toxic non-steroidal anti-inflammatories) may also contribute
to CKD in this population. With respect to patients with
known lupus nephritis, available data suggest wide variation
in long-term clinical outcome of patients who have SLE
nephritis.13–20 It is also important to define the rate of kidney
function decline in patients with renal autoimmune involve-
ment to help clinicians balance the risks of immunosuppres-
sive drugs with the risk of progressive CKD.
Accordingly, we have studied the course of long-term
kidney function in a large predominantly Caucasian incep-
tion cohort of prospectively followed up subjects with SLE
(with and without known renal involvement), in an effort to
better understand the long-term course of kidney function in
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these individuals. We determined the proportion of patients
who develop CKD according to the KDIGO (Kidney Disease:
Improving Global Outcomes) 21 definitions to contextualize
their loss of kidney function and characterize the risk of CKD
according to internationally accepted guidelines. Recognizing
that this definition may not reflect CKD that is likely to
evolve into advanced renal insufficiency, we also identified
whether the CKD was progressive in nature by studying the
rate of renal function decline over time. Finally, we related
clinical parameters to the rate of renal function decline to
maximize our ability to refine therapeutic goals to prevent
loss of kidney function.
RESULTS
Characteristics of inception cohort
This was a predominantly female (87%) Caucasian (77%)
cohort; the balance was African Caribbean (9.4%) or Chinese
(7%). The mean body mass index at the time of enrollment
was 27.4±8.1 kg/m2. Only 9 subjects (1.8%) were diabetic,
and 109 subjects (22%) smoked at baseline.
During 11 years of follow-up, half of the subjects (53%)
developed evidence of renal involvement of SLE according to
the ACR criteria.12 An additional 35 subjects developed
diabetes during the course of follow-up; a total of 8.7% ever
had diabetes.
Development of progressive and non-progressive CKD
In total, 18% of the population had CKD at the time of last
follow-up (Table 1). Of patients who never had ACR-defined
renal lupus, only a small group had evidence of CKD (n¼ 28)
according to the KDIGO criteria at the time of last follow-up.
These patients were older (54 years) and had renal
insufficiency at the time of enrollment, but had a low rate
of renal function decline over time (0.662ml/min per
1.73m2 per year), suggesting that these patients have
non-progressive CKD. Of patients who did have ACR-defined
renal lupus, 63/266 (24%) had CKD at last follow-up.
Although these subjects also had impaired renal function at
the time of enrollment, they were younger (39 years) and
their rate of renal function decline was 4.35ml/min per
1.73m2 per year, suggesting a progressive course. Only six
patients developed end-stage renal disease requiring long-
term dialysis or transplantation; all had renal lupus nephritis.
Although the adjusted mean SLE disease activity index
(SLEDAI) (AMS) score across the four groups differed, the
non-renal-adjusted mean SLEDAI did not and the difference
in AMS was mostly related to the presence of renal disease
activity parameters. In addition, measures of c-reactive
protein (CRP) did not differ across groups, although there
was a trend toward a higher level in the group of older
individuals with non-progressive CKD without nephritis
(P40.05). Patients with CKD, according to the KDIGO
definition, had higher cholesterol, sustained time-averaged
(TA) mean arterial pressure (MAP), and sustained TA
proteinuria.
During the course of their follow-up, 35 patients
developed diabetes (9 patients had diabetes at the time of
enrollment). The proportion of patients with diabetes
diagnosed either at inception or during follow-up did differ
across groups (Table 1), and the impact of this on kidney
function decline is described below. There was no difference
in the proportion of patients who smoked (33%) at the time
of enrollment or during the course of follow-up across
groups.
Predictors of progressive CKD
To better understand predictors of the rate of kidney function
loss, clinical variables were related to the rate of renal
function decline as previously described.22–27 The mean rate
of renal function decline or slope of estimated glomerular
Table 1 | Characteristics of patients according to whether they ever had lupus renal involvement (by the ACR criteria) and
development of CKD
Full cohort
(N=504)
Never renal
involvement,
no CKD (N=210)
Never renal involvement,
CKD at last
follow-up (N=28)
Renal involvement,
no CKD (N=203)
Renal involvement,
CKD at last
follow-up (N=63)
Age at enrollment (years) 35±14 35±12 54±14 33±12 39±17
Duration of follow-up (years) 11.3±8.3 9.6±7.4 11.6±8.3 12.6±8.8 12.7±8.5
eGFR at enrollment
(ml/min per 1.73m2)*
89±29 95±22 63±20 94±29 64±34
Rate of renal function decline*
(ml/min per 1.73m2 per year)
1.513±7.1 1.255±6.0 0.662±3.1 1.018±6.3 4.35±11.9
Adjusted mean SLEDAI 5.1±3.4 4.4±2.9 3.6±2.2 5.4±3.4
(non-renal 3.7±2.8)
7.2±4.2
(non-renal 4.2±2.2)
Average CRP/hsCRP 6.03/4.2 5.0/3.4 12.3/9.5 6.3/4.4 6.5/5.0
TA cholesterol* 5.1±1.11 4.8±0.8 5.3±1.0 5.1±1.1 6.1±1.5
TA MAP* (mmHg) 93.0±9.4 89.9±8.3 99.7±7.5 92.5±8.4 102.1±8.4
TA proteinuria* (g/day)
med (min, max)
0.71 (0, 10) 0.09 (0, 0.45) 0.11 (0.05, 0.45) 0.35 (0, 6.2) 1.1 (0.06, 10)
Diabetes, N (%)* 44 (8.7) 10 (4.8) 0 24 (11.8) 10 (15.9)
Deceased at last follow-up* (%) 73 (14.5) 14 (6.7) 6 (21) 29 (14) 24 (38)
Abbreviations: ACR, American College of Rheumatology; ANOVA, analysis of variance; CKD, chronic kidney disease; CRP, c-reactive protein; eGFR, estimated glomerular
filtration rate; hsCRP, high-sensitivity CRP; MAP, mean arterial pressure; SLEDAI, systemic lupus erythematosus disease activity index; TA, time-averaged.
Values are mean±s.d., unless otherwise indicated. Variables with statistically significant differences across groups are indicated by * (*Po0.05 for ANOVA).
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filtration rate (eGFR) of all subjects was 1.5ml±7.1ml/min
per 1.73m2 per year. The age at first presentation, eGFR
at presentation, TA sustained proteinuria, TA cholesterol,
adjusted mean SLEDAI score (including renal components),
number of renal flares, and MAP at inception were predic-
tive of the rate of progression of renal function decline
by univariate linear regression analysis (Table 2). There was a
statistically important interaction between cholesterol and
proteinuria.
By univariate analysis, it was determined that several
variables were not related to the rate of renal function
decline. Slope did not differ according to smoking status or
race. Although more patients with lupus nephritis and CKD
developed diabetes during the course of follow-up, diabetes
was not associated with a more rapid rate of renal function
decline. The adjusted mean non-renal SLEDAI was not
predictive of slope, nor were the average CRP or high-
sensitivity CRP values. The body mass index, 24-h urine
protein, anti-ds-DNA, and C3 titers at the time of first
presentation were not predictive of the slope, nor was the TA
MAP; these variables were therefore not considered in the
multivariate model. There were too few male subjects to
detect effects of gender on the rate of renal function decline.
The rate of renal function decline did not differ between
subjects whether they did or did not receive ACE inhibitors
or angiotensin receptor blockers.
When the multivariate model was analyzed, age and
baseline MAP no longer remained a significant predictor of
slope. However, the baseline renal function at the time of
presentation, TA proteinuria, TA cholesterol, and adjusted
mean SLEDAI score (with renal components) remained
significant independent predictors of the rate of renal
function decline (adjusted R2 for the multivariate model is
0.245, Po0.0001).
Impact of sustained proteinuria on progression
The rate of renal function decline differed significantly
according to the level of TA proteinuria (Table 3, Po0.05
adjusted for unequal variance). The slope was 6–7 times
greater in subjects with over 2 g/day of TA proteinuria
compared with subjects with under 2 g/day of proteinuria
(adjusted P-values o0.05).
Impact of resolution of renal flares on progression and
survival
Although many patients had renal SLE involvement accord-
ing to the ACR criteria, 98 subjects had biopsy-proven,
WHO or ISN-RPS class III, IV, or V lupus nephritis (Table 4).
Subjects who did not reach a complete or partial remission of
their nephritis flare had a rate of renal function decline that
was 30 times faster than that of subjects who did (Po0.05).
CKD and cohort mortality
At the time of last follow-up, 15% of subjects had died
(Table 1). The rate of renal function decline was significantly
related to the risk of death; when accounting for renal
function at the time of inception, for every 1ml/min per
1.73m2 faster rate of GFR loss per year, there was a 1.15-fold
increased risk of death (95% confidence interval for hazard
ratio 1.11–1.19, Po0.0001). The primary cause of death
Table 2 | Factors predictive of the rate of renal function decline
Univariate regression Multivariate regression
Variable Unadjusted b-coefficient±s.e. P-value b-Coefficient±s.e. P-value
Age at inception 0.059±0.022 0.01 0.03±0.03 0.46
eGFR at inception 0.077±0.010 o0.001 0.094±0.013 o0.0001
MAP at inception 0.05±0.02 0.1 0.04±0.03 0.2
TA proteinuria 0.965±0.292 o0.001 3.5±1.4 0.02
Mean average cholesterol 1.320±0.276 o0.001 1.25±0.4 o0.0001
Interaction term (proteinuria cholesterol) See text 0.55±0.20 0.009
Adjusted mean SLEDAI with renal components 0.314±0.092 o0.001 0.28±0.11 0.03
Number of renal SLE flares 0.561±0.189 0.003 0.5±0.23 0.25
Abbreviations: eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index;
TA, time-averaged.
Results of univariate and multivariate linear regression analyses. The b-coefficients provided are derived from the full multivariate model.
Table 3 | Rate of renal function decline according to category
of TA proteinuria
TA urine protein
excretion (g/day)*
Number of
subjects
Slope of eGFR (ml/min per
1.73m2 per year)
0–1 275 1.15±5.37
1–2 32 0.32±8.98
42 36 6.68±14.6
Abbreviations: eGFR, estimated glomerular filtration rate; TA, time-averaged.
*Po0.05 comparing slope across categories of TA proteinuria.
Table 4 | Clinical characteristics of subjects with biopsy-
proven WHO class III, IV, or V SLE nephritis, and the rate
of renal function decline according to remission status
Baseline (n=98)
Number with only class V lesion 16
Baseline eGFR (ml/min per 1.73m2) 81.08±30.6
Median baseline proteinuria (range) (g/24 h) 1.00 (0.2–36)
Duration of follow-up (years) 12.36±8.4
Follow-up Slope (ml/min per
1.73m2 per year)±s.d.
All subjects 1.38±6.8
Complete remission, n=73 0.429±6.34
Partial remission, n=9 0.058±5.87
No remission, n=16 6.49±7.33
Abbreviations: eGFR, estimated glomerular filtration rate; SLE, systemic lupus
erythematosus.
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(ICD-9 code) was available for 84% of the deceased; half of
the coded deaths were attributable to cancer or sepsis, and
the remainder was mostly due to cardiovascular disease.
The patient mortality during follow-up is illustrated in
Figure 1. This figure is provided for descriptive purposes, as
the survival time would be highly correlated with the time to
development of CKD.
In the 98 patients with biopsy-proven lupus nephritis,
mortality risk was evaluated using survival analysis; survival
was calculated from the time of first biopsy evidence of class
III, IV, or V nephritis. The risk of mortality in this subgroup
was not related to renal function at the time of biopsy, but
was independently related to sustained proteinuria and MAP
during the 2 years of follow-up following biopsy.
DISCUSSION
We studied a large, primarily Caucasian inception cohort of
subjects with and without renal SLE involvement to describe
the burden of CKD in this population and identify risk
factors associated with progressive renal function decline.
Our first finding was that two distinct groups of patients
with SLE develop CKD during long-term follow-up. The first
group includes individuals diagnosed with SLE at an older
age who do not have documented ACR-defined autoimmune
renal involvement. The second group comprises indivi-
duals with renal lupus who have sustained proteinuria and
dyslipidemia. Given the important contribution of age and
baseline renal function to the KDIGO definition of CKD
used in this study, the rate of renal function decline in
these patients is an important indicator as to whether this
represents stable or progressive CKD. The subgroup of
patients with ‘CKD’ who were older at the time of diagnosis
(n¼ 28) had minimal renal function decline during the
period of follow-up (0.662±3.1ml/min per 1.73m2 per
year), which is comparable to that observed in healthy
populations.28–30
The relatively low rate of renal function decline observed
in our cohort as a whole is surprising,11,15,31 given the
prevailing theory that systemic inflammation contributes
directly to kidney injury and progressive CKD,2–4 potentially
by precipitating microvascular injury. SLE is regarded as
a prototype of systemic inflammatory conditions, and this
systemic inflammation is thought to contribute to the
elevated risk of cardiovascular events in this population;32
however, this has not previously been extended to the study
of loss of kidney function in patients with SLE who do
not have documented autoimmune renal involvement. The
incremental risk of kidney failure is likely small if one
projects this rate of renal function declines to 30 years of
follow-up. One possible explanation for this observation is
that the majority of the population consists of premenopau-
sal women, and the protective effects of estrogen during the
observation period may in part counterbalance the effects of
systemic inflammation on the vasculature,33 unless patients
have severe or poorly responsive autoimmune renal disease.
Another possible factor affecting CKD risk in this popula-
tion is the competing risk of death, which considers that
premature mortality prevents the development of CKD.
Finally, it may be that the inflammatory aspect of lupus was
not as prominent in this cohort; patients without SLE-related
nephritis had relatively low adjusted mean SLEDAI scores,
reflecting low average levels of disease activity over the period
of follow-up.
Our second finding is that in the cohort of patients with
lupus nephritis, both TA proteinuria and cholesterol are
important interrelated and modifiable risk factors for
progressive loss of kidney function. This approach relating
TA variables to the rate of kidney function decline (eGFR
slope) in patients with SLE builds upon previous work
indicating that, in the shorter term, proteinuria is a predictor
of doubling of serum creatinine and kidney failure in patients
with SLE nephritis.11 This approach also permits finer
resolution in terms of proteinuria targets for long-term
preservation of kidney function in patients with SLE.
Although sustained proteinuria is recognized as the most
important predictor of the rate of renal function decline in
primary glomerulonephritis,24–26 this has not been as
extensively explored in patients with secondary forms of
glomerular disease. Similar to subjects with immunoglobulin
A nephropathy,26 incremental degrees of sustained TA
proteinuria in our SLE cohort were associated with a more
rapid rate of renal function decline: up to sevenfold greater in
subjects with 42 g/day of TA proteinuria. Furthermore, we
found that subjects who have sustained proteinuria following
biopsy-proven class III, IV, or V nephritis have a 30-fold
greater rate of renal function decline compared with those
who achieve a complete or partial remission of their
proteinuria. Whether this sustained proteinuria represents
residual untreated renal inflammation,34 scarring, or systemic
inflammation is not known. Although these findings high-
light the clinical importance of sustained proteinuria, they
also emphasize the need for careful assessment of risk and
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Figure 1 | Survival from the time of inception, according to
whether subjects ever had lupus renal involvement (by the
American College of Rheumatology (ACR) criteria) and
development of CKD at last follow-up. Group 1: no renal
involvement of lupus, no CKD; Group 2: no renal involvement of
lupus but did develop CKD; Group 3: renal involvement of lupus
but no CKD; Group 4: renal involvement of lupus and CKD at last
follow-up.
Kidney International (2011) 79, 914–920 917
HN Reich et al.: The risk of progressive CKD in lupus erythematosus o r ig ina l a r t i c l e
benefit of therapy. Half of the mortality observed in patients
was attributable to sepsis or cancer; although these deaths
may be related to renal disease, it is equally plausible
that they relate to complications of intensified immuno-
suppression.
Several study limitations require discussion. First, the
renal outcomes of our cohort, even those with renal SLE
involvement, were more favorable than previously reported
in other populations of patients with lupus nephritis.11,15
One possible explanation is the racial composition of our
cohort, which was predominantly Caucasian. Indeed, race is
an important predictor of outcome of lupus nephritis, and
wide variations in short- and long-term renal outcome have
been described,15,35,36 with particularly poor outcomes in
patients of African and Caribbean descent. Although we did
not observe differences in outcome according to race, our
study may have had insufficient representation of vulnerable
groups of interest. In addition, the impact of differences in
socioeconomic status was not studied in this cohort of
patients with universal health-care access. Next, we used a
linear model to measure the rate of renal function decline
(slope) to identify risk factors for progressive renal impair-
ment. Slope-based studies use individually observed change
in renal function over time as the outcome of interest37 to
identify risk factors for loss of renal function,38 or impact of
interventions 39 in CKD, and these analyses rely on the
assumption that loss of renal function is linear over time.40–42
Although SLE is characterized by flares of disease activity, we
hypothesized that, in addition to flares of both renal and
extrarenal inflammatory disease activity, ongoing proteinur-
ia, hypertension, and dyslipidemia contribute to progressive
renal function decline in subjects with SLE. It is possible that
nonlinear techniques to model renal function decline may
have identified additional predictors of CKD. Another
consideration with slope-based analyses is that some of the
covariates may be dependent upon the duration of follow-up
(for example, number of renal flares), which in this analysis
was not fixed. However, using this approach has allowed us to
contextualize the course of lupus-related kidney disease in
relation to that of patients with idiopathic forms of kidney
disease,24–26 and the findings with respect to predictors of
renal deterioration are surprisingly similar. Finally, as this is
not a randomized study, the relationship between treatment
and outcome in this study is primarily descriptive; the impact
of specific interventions on the risk of CKD was beyond the
scope of this study.
In summary, despite exposure to a milieu of systemic
inflammatory disease, the risk of progressive CKD in patients
with SLE is low; progressive CKD occurs primarily in
individuals who have autoimmune renal involvement with
persistent sustained proteinuria and dyslipidemia. The rate of
renal function decline in the remainder of the cohort is
comparable to that described in the general population, and
the clinical impact on risk of end-stage kidney disease is likely
modest. Although the favorable renal outcome may reflect
aggressive immunosuppressive regimens, the high rate of
non-renal mortality emphasizes the need for ongoing trials
to define the goals of maintenance immunosuppressive
treatment, to help balance risks of treatment with prevention
of progressive CKD.
MATERIALS AND METHODS
Subjects
Since 1970, the University of Toronto Lupus Clinic (UTLC) has
prospectively followed up patients with a confirmed diagnosis of
SLE43 (that is, those fulfilling four of the 1971 or 1982 ACR
classification criteria12 or three ACR criteria plus having a diagnostic
histologic lesion of SLE on renal or skin biopsy). Patients are
followed up according to a standard protocol in a manner consistent
with the principles of the Declaration of Helsinki. For each patient, a
complete history, physical examination, and laboratory values are
recorded at entry and at intervals of 2–4 months, with the exception
of certain laboratory tests, such as serum lipid concentrations, which
are carried out annually.
Data were obtained from an inception cohort of 631 subjects
entered into the UTLC within 1 year of diagnosis of SLE, who were
followed up in the UTLC up to March 2008. Of the 631 subjects, 116
were excluded because they had o1 year of follow-up, and 11 were
excluded because they had measures of creatinine o3. Data from
504 subjects were available for analysis; at the time of final analysis,
30% were lost to follow-up; available data were included in the
analysis but censored at their last visit.
Rate of renal function decline—slope
Given that the development of CKD may depend upon the duration
of follow-up, predictors of progressive CKD were studied in relation
to the rate of renal function decline, as previously described.22–27
The rate of renal function decline was expressed as the slope of eGFR
(calculated by MDRD (Modification of Diet in Renal Disease Study)
formula44,45) obtained by fitting a straight line through the
calculated eGFR values using linear regression and the principle of
least squares. This was plotted and visually examined for each
patient. As previously described, outlier measurements (that is,
eGFR of X40% within a 3-month time frame not sustained or
associated with changes in immunotherapy) were removed from the
calculation;24–27 this was carried out in less than 10 curves. CKD was
defined according to the KDIGO guidelines,21,46 as a sustained eGFR
p60ml/min/1.73m2.
Clinical parameters
MAP. For each patient, an average MAP was determined for
each 6-month block during follow-up; the average of MAP for every
6-month period is represented by the time-average (TA) MAP.
Proteinuria. Similar to the TA MAP, the TA proteinuria
represents an average of the mean of 24-h proteinuria measurements
for every 6-month period. For example, if a patient had three
measurements in a 6-month block and four measurements in the
subsequent 6-month block, a mean value was obtained for each of
the 6-month blocks, and the TA proteinuria is derived from the
average of these two values.
Cholesterol. In a similar manner to MAP and proteinuria, an
average mean cholesterol measurement was calculated for every
patient.
CRP. CRP was serially and prospectively measured on registry
patients from September 2000 to 2003. This was subsequently
replaced by the high-sensitivity CRP assay. Average mean CRP and
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high-sensitivity CRP values were calculated for every patient
according to assay results available for analysis.
Assessment of SLE disease activity. This was based on the
SLEDAI-2K, recorded prospectively at predetermined intervals in
the database.47 An adjusted mean SLEDAI score (AMS) was calcu-
lated for each patient and describes disease activity over time. It is
equivalent to the area under the curve of SLEDAI-2K over time
divided by time interval.48 To isolate the non-renal components of
the SLEDAI score, the renal components were removed from the
calculated SLEDAI, and an adjusted mean non-renal SLEDAI was
calculated in a similar manner.
Assessment of remission status. Although half of patients had
renal involvement according to ACR criteria, 98 had biopsy-proven
class III, IV, or V nephritis. We studied the impact of remission
status in this subgroup. Remission status following a renal flare was
defined as per Chen et al.49 Complete remission was defined as
attainment of a serum creatinine levelp120 mmol/l (1.4mg/dl) and
24-h urine protein excretion o0.3 g/day or negative by dipstick at
any time following the initial flare. Partial remission was defined as a
serum creatinine level that returned to within 25% of baseline before
the flare, and a X50% reduction in proteinuria to under 1.0 g/day
(p0.3 g/l by dipstick). All other patients who had a flare but did not
meet the criteria of complete or partial remission at any time
following their biopsy were considered to have no remission.
Statistical analysis
Data were analyzed using SAS (version 9.1, SAS Institute, Cary, NC).
For descriptive statistics, normally distributed variables are ex-
pressed as mean±s.d. and compared using t-test or analysis of
variance as required, accounting for unequal variance as required.
Variables with a skewed distribution or non-parametric variables are
expressed as median and range, and were compared using the
Mann–Whitney U-test. Categorical associations were compared
using Fisher’s exact test. A two-tailed Po0.05 was considered
statistically significant.
For determining statistical associations with kidney function
decline, given that the development of CKD depends upon the
duration of follow-up, and that CKD may not be progressive,
clinical TA variables were studied in relation to the rate of renal
function decline in the full inception cohort population, as
previously described.22–27 For multivariate analysis, only variables
significantly associated with slope by univariate analysis, at a
threshold P-value of 0.1, were included in the multivariate model to
determine independent predictors of slope. The effect of renal SLE
flares on rate of renal function decline was considered as both a
continuous variable (number of flares, Table 2) and a dichotomous
variable (flare yes/no). As proteinuria distribution was skewed (at
presentation and time averaged), natural log-transformed values
were used in the regression analysis, and similar results in terms of
the significance of proteinuria were obtained with non-transformed
data (not shown). Multivariate regression models were assessed by
stepwise and block entry of variables. Similarly, when studying the
group of patients with biopsy-proven class III, IV, or V nephritis, the
rate of renal function decline was compared across remission
categories.
For analyses relating to patient mortality, Kaplan–Meier survival
curves were generated using GraphPad Prism (version 4, GraphPad
Software, La Jolla, CA) (Figure 1). Given that the development of
CKD is dependent upon time of follow-up, this figure was
constructed for descriptive purposes, but statistical comparisons
were not carried out across the four groups. Survival in patients with
biopsy-proven lupus nephritis was analyzed using Cox regression
analysis. Time was calculated from the time of first diagnosis of
biopsy-proven class III, IV, or V nephritis to death. Given that TA
variables may be highly correlated with time to event, in addition to
reporting the relationship between TA variables and survival, we
calculated the mean proteinuria and average MAP during the first
2 years of follow-up after kidney biopsy, and related this variable
to survival in all patients who had these data available for analysis
(n¼ 50). Therapeutic interventions are described in the Supple-
mentary Table S1 online.
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